Centocor Hits A Triple With Golimumab
This article was originally published in The Pink Sheet Daily
Executive Summary
Three Phase III trials prove TNF blocker works in RA – even after others in the class failed.
You may also be interested in...
J&J/Centocor Files Golimumab In Three Indications
Company seeks approval in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
J&J/Centocor Files Golimumab In Three Indications
Company seeks approval in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
J&J Golimumab BLA Filing Planned For First Half 2008 In Three Indications
Johnson & Johnson’s Centocor unit is positioning the next generation anti-TNF as a once-monthly treatment.